TJ Maxx vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
TJX Companies (NYSE: TJX) flagship off-price banner; parent reported $56.4B revenue FY2025 (+4%); 5,085 stores globally; treasure hunt retail model with constantly rotating merchandise mix and 131 new locations added in FY2025.
About
TJ Maxx is the flagship retail banner of TJX Companies, America's largest off-price retailer, founded in 1976 and headquartered in Framingham, Massachusetts. The brand was built on the "treasure hunt" retail model: buying excess inventory, overruns, and closeouts from manufacturers and department stores at steep discounts, then passing those savings to shoppers in a constantly rotating merchandise mix. This opportunistic buying strategy — executed by one of retail's largest buying organizations — is the core competitive technology that competitors cannot easily replicate.\n\nTJ Maxx stores carry apparel, accessories, footwear, home goods, beauty, and giftware across thousands of locations in the US, with TJX's broader portfolio also including Marshalls, HomeGoods, HomeSense, and Sierra. The physical store experience — browsing through unpredictable inventory to find brand-name items at 20–60% below department store prices — creates the addictive treasure hunt dynamic that drives frequent repeat visits. This model has proven highly durable against e-commerce disruption, as the discovery experience does not translate well to online retail.\n\nTJX Companies generated $56.4B in revenue in FY2025, a 4% increase, operating over 5,085 stores globally with 131 net new locations added. The company's off-price model has thrived as value-conscious consumers trade down from department stores and as retail inventory gluts create buying opportunities. TJ Maxx remains the dominant brand within TJX's portfolio and a bellwether of the off-price retail sector's resilience across economic cycles.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.